Syncom Formulations (India) Ltd

BSE
SYNCOMF •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Syncom Formulations (India) Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
115.24% Gain from 52W Low
11
TTM PE Ratio
Above industry Median
57.1
Price to Book Ratio
Below industry Median
5
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is much higher than 1
2.2
RSI
RSI is mid-range
64.1
MFI
MFI Overbought
73

Syncom Formulations (India) Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Syncom Formulations (India) Ltd shareholding Pattern

Promoter
50.6%
Foreign Institutions
0.1%
Public
49.3%
Promoter
50.6%
Foreign Institutions
0.1%
Public
49.4%
Promoter
50.6%
Public
49.4%
Promoter
50.6%
Public
49.4%
Promoter
50.6%
Public
49.4%
Promoter
50.6%
Public
49.4%
Foreign Institutions
0.6%
Foreign Institutions
3.4%

Syncom Formulations (India) Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
15.00
10Day EMA
14.70
12Day EMA
14.50
20Day EMA
14.10
26Day EMA
13.80
50Day EMA
13.40
100Day EMA
13.20
200Day EMA
12.50
5Day SMA
15.20
10Day SMA
14.70
20Day SMA
13.70
30Day SMA
13.30
50Day SMA
13.10
100Day SMA
13.10
150Day SMA
13.80
200Day SMA
12.80
Delivery & Volume
Resistance & Support
14.76
Pivot
Resistance
First Resistance
15.52
Second Resistance
16.05
Third Resistance
16.81
Support
First Support
14.23
Second support
13.47
Third Support
12.94
Relative Strength Index
64.13
Money Flow Index
72.97
MACD
0.69
MACD Signal
0.52
Average True Range
0.83
Average Directional Index
34.68
Rate of Change (21)
18.31
Rate of Change (125)
-1.83

Syncom Formulations (India) Ltd Company background

Founded in: 1988
Managing director: Vijay Shankarlal Bankda
Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.92. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing setup at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections Dry Vial injections, Dry Syrups, Ointments and Inhalers.The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.94 was completed in 1995.During the year 199798, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.During the year 199899 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.During the year 19992000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department byputting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installedcapacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of thecapacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulationsections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 200203. The expanded capacities were made available for production from May, 2003.In 2007, the Company launched a new division Cratus Life Care to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 200708. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008.In 202021, the business activity of the Company was expanded by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum and to modernize the Tablet Department within an overall cost of Rs. 4031.50 Lakhs whichwas funded by the issuance of fresh share capital to meet the overall cost of the project.
Read More

Syncom Formulations (India) Ltd FAQs

The past 1-year return of Syncom Formulations (India) Ltd [SYNCOMF] share was 109.95. The Syncom Formulations (India) Ltd [SYNCOMF] share hit a 1-year low of Rs. 7.15 and a 1-year high of Rs. 18.65.

You can easily buy Syncom Formulations (India) Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -